JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia

  • 0Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Kirstein 382, Boston, MA 02215, USA.
Circulation +

|

January 21, 2012

|

January 21, 2012

Related Experiment Videos

Contact us if these videos are not relevant.

View abstract on PubMed

Summary

This summary is machine-generated.

The soluble fms-like tyrosine kinase 1/placental growth factor (sFlt1/PlGF) ratio effectively predicts preeclampsia complications within two weeks. This biomarker offers improved accuracy for risk stratification and management in early-term pregnancies.

Area Of Science

  • Reproductive Medicine
  • Maternal-Fetal Medicine
  • Biomarker Discovery

Background

  • Preeclampsia pathogenesis involves an imbalance of circulating angiogenic factors.
  • The soluble fms-like tyrosine kinase 1 (sFlt1)/placental growth factor (PlGF) ratio is a key indicator of this imbalance.

Purpose Of The Study

  • To evaluate the predictive value of the sFlt1/PlGF ratio for adverse maternal and perinatal outcomes in women with suspected preeclampsia.
  • To assess the ratio's accuracy compared to existing diagnostic methods.

Main Methods

  • Prospective study of 616 women evaluated for suspected preeclampsia.
  • Measurement of plasma sFlt1 and PlGF levels at presentation.
  • Analysis of the association between the sFlt1/PlGF ratio and adverse outcomes within two weeks.

Main Results

  • Elevated sFlt1/PlGF ratios were significantly associated with adverse outcomes (P<0.0001).
  • In women presenting before 34 weeks, the ratio demonstrated markedly higher predictive accuracy (OR 47.8) compared to standard clinical factors.
  • The sFlt1/PlGF ratio significantly improved prediction models for adverse outcomes (AUC 0.93 vs 0.84).

Conclusions

  • The circulating sFlt1/PlGF ratio is a valuable predictor of adverse outcomes within two weeks in women with suspected preeclampsia presenting before 34 weeks.
  • This biomarker offers superior accuracy to current approaches for risk stratification and management.
  • Further studies are recommended for validation.

Related Experiment Videos

Contact us if these videos are not relevant.

Related Concept Videos